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Abstract
Fluoroquinolone-associated tendinopathy is well described. This adverse effect however does not
appear to be widely known among medical practitioners. We hereby described a case of
ciprofloxacin-associated tendinopathy for which the adverse drug reaction was not suspected
initially and the patient was inappropriately reassured and incorrectly advised to complete the
antibiotic course. Given the frequent use of fluoroquinolones in clinical practice and the potential
for severe disability from tendon rupture, we consider it important to remind your readers of this
uncommon but potentially devastating adverse drug reaction.
Background
Fluoroquinolones are a family of broad-spectrum bacteri-
cidal antibiotics that are frequently used in the treatment
of a wide range of infections. They are considered to be
relatively safe and well tolerated. However, although it is
well documented that fluoroquinolones predispose to
tendinopathy, this adverse effect does not appear to be
widely known among medical practitioners. Given the fre-
quent use of fluoroquinolones in clinical practice and the
potential for severe disability from tendon rupture, we
consider it important to remind your readers of this
uncommon but potentially devastating adverse drug reac-
tion.
Case presentation
A 42-year-old woman presented to the emergency depart-
ment of a district general hospital with acute onset of gen-
eralised pain several hours after taking ciprofloxacin for
presumed urinary tract infection. Clinical examination at
the time was unremarkable. She was reassured and
advised to finish the 5-day course of antibiotics. Her
symptoms persisted after 3 weeks and she was referred for
a rheumatological opinion.
She described feeling that the tendons of her hands, left
knee and left ankle were "inflamed". She had morning
stiffness lasting 30 minutes and the pain was worse at the
end of the day. She had pain on walking and performing
simple tasks with her hands. There was no joint swelling
and she denied other symptoms. She used ibuprofen as
required for symptom control.
Her past medical history included uterine fibroids and
recurrent "cystitis" secondary to dystonic bladder awaiting
further investigations. In addition to a busy job she pur-
sued a wide range of sporting activities.
Examination of the hands revealed tenderness of the
flexor and extensor tendons with poor grip secondary to
pain. The patellar and Achilles tendons were tender to pal-
pation but no swelling was detected. There was no swell-
ing or tenderness of her peripheral joints. Laboratory
investigations revealed normal inflammatory markers,
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Autoimmune serology was negative. Ultrasound examina-
tion of her Achilles tendons showed no evidence of a ten-
don tear or rupture.
A diagnosis of ciprofloxacin-related tendinopathy was
made. She was treated with ibuprofen as required and a
graded exercise programme. Her symptoms improved
after 3 weeks and completely resolved after 4 months.
Discussion
The first case of fluoroquinolone-associated tendinopathy
was reported in 1983 [1]. Since then, nearly 100 case
reports have been published, many of which originate
from France, due to the publicity generated in that coun-
try.
The incidence of this condition is not clear. A rate of 2.9
per 1000 prescriptions for tendinitis has been reported in
one study [2] with an overall excess risk of 3.2 cases per
1000 patient years [3]. With prescription-event monitor-
ing, a rate of 2.4 per 10,000 patients for tendinitis, and 1.2
per 10,000 patients for tendon rupture was found [4]. Risk
factors include age over 60, corticosteroid therapy, sport-
ing activity, history of musculoskeletal disorders, renal
failure and diabetes [3,5,6].
The commonest presenting complaint of fluoroqui-
nolone-associated tendinopathy is pain, typically of sud-
den onset. Other symptoms include swelling, warmth,
tenderness, erythema or itchiness over tendon sites and
functional disability. Bilateral involvement is common.
Clinical findings include tendon swelling, thickening or
oedema [5,6]. The commonest tendon affected is the
Achilles tendon, but other tendons can also be affected
[5,6]. Up to 50% of patients may develop tendon rupture
with nearly one-third of these in patients taking long-term
corticosteroid therapy [5]. It is noteworthy that up to half
of the tendon ruptures occurred without warning [5,6].
The latency period between the start of fluoroquinolone
treatment and symptom ranges from a few hours to a few
weeks, with a mean of 6–10 days. Most patients recover
within 2 months after cessation of therapy, but over a
quarter of patients suffer with persistent pain and disabil-
ity [6]. Other musculoskeletal side-effects of quinolones
include arthropathy, myalgia and myopathy.
The diagnosis is usually clinical. Ultrasound and magnetic
resonance imaging of the affected tendons is helpful in
identifying tendon tear or rupture.
Management is largely symptomatic with discontinuation
of the offending antibiotics, use of analgesics/anti-inflam-
matory medications and physiotherapy. Rest and
splinting may be necessary. Tendon rupture often requires
surgical repair.
The pathogenesis of fluoroquinolone-related tendinopa-
thy has not been established. Several mechanisms such as
direct toxic effect [7,8] and ischaemic injury [9] have been
proposed.
This case highlights the importance of suspecting possible
drug reaction when there is a clear temporal relationship
between treatment and symptoms, regardless of how
commonplace the medication concerned. Indeed, the
drug information on quinolones in the British National
Formulary (BNF) includes the CSM advice on tendon
damage associated with quinolone use [10]. It advises
immediate discontinuation of treatment if tendinitis is
suspected.
In summary, we have presented a case of ciprofloxacin-
associated tendinopathy and highlighted the importance
of recognising a potentially disabling complication of this
common antibiotic.
Conclusion
Fluoroquinolone-associated tendinopathy should be con-
sidered in patients with musuloskeletal symptoms associ-
ated with recent use of fluoroquinolones.
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